# US 2024/0189252 A1 · Dextromethorphan transdermal delivery device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189252 A1
- Document ID: US20240189252A1
- Status: Published application
- Kind: A1
- Application number: 18/381,849
- Filed: 2023-10-19
- Published: 2024-06-13
- Earliest claimed: 2017-10-04
- Assignees: Shinkei Therapeutics, Inc.
- Applicants: Shinkei Therapeutics, Inc.
- Inventors: Suresh BORSADIA
- Web page: https://patentgrep.com/patent/US20240189252A1

## CPC

- A61K 9/7038: {Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer}
- A61K 9/7061: {Polyacrylates}
- A61K 9/7069: {obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/49: Cinchonan derivatives, e.g. quinine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method of treating a neurological disorder in a subject in need thereof, the method comprising transdermally administering to the subject a therapeutically effective amount of dextromethorphan.

### Claim 31 (depends on 30)

The method of claim 30, comprising applying a transdermal delivery device to the skin of the subject once daily, wherein the transdermal delivery device comprises an adhesive layer comprising an adhesive in the amount of about 65% to about 85%, dextromethorphan in an amount of about 2% to about 12%, a permeation enhancer in an amount of about 6% to about 12%, and optional other ingredients in an amount of about 0% to about 20%.

### Claim 32 (depends on 31)

The method of claim 31, wherein the permeation enhancer is isopropyl myristate in an amount of about 10% of the adhesive layer.

### Claim 33 (depends on 31)

The method of claim 31, wherein the transdermal delivery device is configured to provide dextromethorphan about 15 mg/day to about 40 mg/day to the subject.

### Claim 34 (depends on 30)

The method of claim 30, wherein the subject does not suffer from a cough and/or does not need an antitussive.

### Claim 35 (depends on 30)

The method of claim 30, wherein the subject is an extensive metabolizer of dextromethorphan.

### Claim 36 (depends on 30)

The method of claim 30, wherein the subject is a poor metabolizer of dextromethorphan.

### Claim 37 (depends on 30)

The method of claim 30, wherein the subject is sensitive to or otherwise intolerant to quinidine.

### Claim 38 (depends on 30)

The method of claim 30, wherein the subject is not co-administered a CYP2D6 inhibitor.

### Claim 39 (depends on 30)

The method of claim 30, wherein the neurological disease or disorder is depression, stroke, traumatic brain injury, seizure, pain, methotrexate neurotoxicity, Parkinson's disease, autism, or a combination thereof.

### Claim 40 (depends on 30)

The method of claim 30, further comprising administering to the subject one or more additional active agents selected from amlodipine, a capsaicinoid, an opioid agonist, an adenosinergic agonist, 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, gabapentin, and pharmaceutically acceptable salts thereof.
